Provided by Tiger Fintech (Singapore) Pte. Ltd.

Bio-Rad Laboratories

256.68
+2.210.87%
Post-market: 256.680.00000.00%16:33 EDT
Volume:1.44M
Turnover:368.07M
Market Cap:7.19B
PE:-3.93
High:256.74
Open:252.58
Low:250.70
Close:254.47
Loading ...

Wells Fargo Sticks to Their Hold Rating for Bio-Rad Laboratories (BIO)

TIPRANKS
·
10 Feb

Processa Pharmaceuticals to Present at the 2025 BIO CEO & Investor Conference

GlobeNewswire
·
07 Feb

QIAGEN Q4 Earnings Miss, Stock Crashes, Margins Expand

Zacks
·
07 Feb

PAHC Stock Falls Despite Q2 Earnings & Revenue Beat, Margins Increase

Zacks
·
07 Feb

Earnings Preview: Bio-Rad Laboratories (BIO) Q4 Earnings Expected to Decline

Zacks
·
06 Feb

Cadrenal Therapeutics to Present at BIO CEO & Investor Conference

Business Wire
·
05 Feb

Lisata Therapeutics to Present at the 2025 BIO CEO & Investor Conference

GlobeNewswire
·
05 Feb

Can-Fite BioPharma to Present Namodenoson at Upcoming BIO CEO Conference

TIPRANKS
·
05 Feb

Tonix Pharmaceuticals to Participate in the 2025 BIO CEO & Investor Conference

GlobeNewswire
·
05 Feb

Can-Fite BioPharma to Present the Namodenoson Anti-Obesity Effect at BIO CEO & Investor Conference 2025

GlobeNewswire
·
05 Feb

Has BioRad Laboratories (BIO) Outpaced Other Medical Stocks This Year?

Zacks
·
04 Feb

GeoVax to Showcase Advancements in Vaccines & Immunotherapies at the 2025 BIO CEO & Investor Conference

NewMediaWire
·
04 Feb

RBC Trims Price Target on Bio-Rad Laboratories to $477 From $481, Keeps Outperform Rating

MT Newswires Live
·
04 Feb

Protalix BioTherapeutics to Participate in the 2025 BIO CEO & Investor Conference

PR Newswire
·
04 Feb

Azitra, Inc. to Present at the BIO CEO & Investor Conference

PR Newswire
·
03 Feb

Press Release: SIMPLY SOLVENTLESS ANNOUNCES OVER SUBSCRIPTION OF PREVIOUSLY ANNOUNCED CONVERTIBLE DEBENTURE FINANCING TO $6.0 MILLION & EXPECTED DELTA 9 BIO-TECH CLOSING DATE OF FEBRUARY 7, 2025

Dow Jones
·
03 Feb